Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 37Observational 13Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 16Neoplasms 11Neuroblastoma 9Lambert-Eaton Myasthenic Syndrome 7Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Leukemia 6Carcinoma, Hepatocellular 6Pheochromocytoma 5Lymphoma 5Leukemia, Myeloid, Acute 5Osteosarcoma 4Neuroendocrine Tumors 4Myelodysplastic Syndromes 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Glioblastoma 4Sarcoma 3Precancerous Conditions 3Paraganglioma 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Insulinoma 3Immunologic Deficiency Syndromes 3Hematologic Neoplasms 3Glioma 3Carcinoid Tumor 3Breast Neoplasms 3Sarcoma, Ewing 2

Interventions

glucarpidase 1Carboxypeptidases 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Expanded_access × Renal Insufficiency × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡